CPH — Cipher Pharmaceuticals Share Price
Last trade - 00:00- CA$317.72m
- CA$349.22m
- $33.36m
- 80
- 44
- 39
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.64 | ||
| PEG Ratio (f) | 0.92 | ||
| EPS Growth (f) | 17.46% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.24 | ||
| Price to Tang. Book | 37.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.87 | ||
| EV to EBITDA | 27.55 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.6% | ||
| Return on Equity | 12.63% | ||
| Operating Margin | 15.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.61 | 21.94 | 20.68 | 21.16 | 33.36 | 50.63 | 54.96 | 8.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +48.47 | +16.44 | +202.18 | -22.34 | -34.18 | +18.44 | +15.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
Directors
- Craig Mull CHM
- Scott Langille CFO
- Diane Gajewczyk VPR
- Arthur Deboeck DRC
- John Mull DRC
- Cathy Steiner DRC
- Christian Godin IND
- Harold Wolkin IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 1st, 2020
- Public Since
- February 25th, 2004
- No. of Employees
- 9
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 25,622,529
- Address
- 5750 Explorer Drive,, Suite 404, MISSISSAUGA, L4W 0A9
- Web
- https://www.cipherpharma.com/
- Phone
- +1 9056025840
- Auditors
- RSM Canada LLP
Upcoming Events for CPH
Similar to CPH
Aptose Biosciences
Toronto Stock Exchange
Aurora Cannabis
Toronto Stock Exchange
Auxly Cannabis
Toronto Stock Exchange
Bausch Health Companies
Toronto Stock Exchange
Canopy Growth
Toronto Stock Exchange
FAQ
As of Today at 19:57 UTC, shares in Cipher Pharmaceuticals are trading at CA$12.40. This share price information is delayed by 15 minutes.
Shares in Cipher Pharmaceuticals last closed at CA$12.40 and the price had moved by +45.88% over the past 365 days. In terms of relative price strength the Cipher Pharmaceuticals share price has outperformed the Toronto Stock Exchange 300 Composite Index by +29.7% over the past year.
The overall consensus recommendation for Cipher Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCipher Pharmaceuticals does not currently pay a dividend.
Cipher Pharmaceuticals does not currently pay a dividend.
Cipher Pharmaceuticals does not currently pay a dividend.
To buy shares in Cipher Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$12.40, shares in Cipher Pharmaceuticals had a market capitalisation of CA$317.72m.
Here are the trading details for Cipher Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CPH
Based on an overall assessment of its quality, value and momentum Cipher Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cipher Pharmaceuticals is CA$16.69. That is 34.63% above the last closing price of CA$12.40.
Analysts covering Cipher Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.63 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cipher Pharmaceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -25.38%.
As of the last closing price of CA$12.40, shares in Cipher Pharmaceuticals were trading -10.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cipher Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 13.64. The shares last closed at CA$12.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cipher Pharmaceuticals' management team is headed by:
- Craig Mull - CHM
- Scott Langille - CFO
- Diane Gajewczyk - VPR
- Arthur Deboeck - DRC
- John Mull - DRC
- Cathy Steiner - DRC
- Christian Godin - IND
- Harold Wolkin - IND